DESCRIPTION
Going to BIO 2010 in Chicago? Foley Hoag is a proud sponsor of BIO 2010, and the exclusive sponsor of the Legal/Intellectual Property Track.
Foley Hoag in the Exhibition Hall
Stop by Booth #2805 in McCormick Place, Chicago and get the latest information on our life sciences services, and register to win an iPhone.
Tuesday, May 4, 2010 — 10:00 a.m. - 6:30 p.m.
Wednesday, May 5, 2010 — 9:00 a.m. - 5:00 p.m.
Thursday, May 6, 2010 — 9:00 a.m. - 5:00 p.m.
Foley Hoag lawyers will moderate and participate in three sessions at BIO 2010 on timely topics in the Legal/Intellectual Property and Impact on Policy in Biobusiness tracks.
What You Need to Know About ITC Section 337 Investigations
Tuesday, May 4, 2:00 pm - 3:30 pm
Despite the global economic downturn during the last few years, the number of International Trade Commission (ITC) Section 337 investigations has skyrocketed by nearly 300 percent since 2004. Similarly, the economy has not slowed patent filings in China, where the SIPO predicts record numbers of filings—the majority of them domestic—for the foreseeable future. Since BIO last addressed this hot topic, several high-profile investigations, including Amgen/Roche and Ajinomoto/Global Bio-Chem, have been decided. This session will provide a comprehensive overview of fast-paced 337 proceedings before the Commission, as well as the unique rules applicable to these investigations. Session participants will hear directly from experienced 337 litigation counsel on both the Amgen/Roche and Ajinomoto/Global Bio-Chem investigations, as well as counsel for the Commission. On this panel, DeAnn Smith and others will review how to develop effective Section 337 investigation strategies for biotechnology companies and what you need to know for an ITC proceeding, including ITC versus district court, how the Commission determines whether an investigation should be commenced; how to file a complaint; temporary relief; accelerated discovery; and the role of expert witnesses.
Commercializing Stem Cell-Based Therapies: Meeting FDA and Other Requirements
Tuesday, May 4, 4:00 pm - 5:30 pm
Recent scientific advances in stem cell research, in combination with the potential for more NIH funding pursuant to new guidelines on federal funding for human embryonic stem cell research, indicate that we are close to human clinical applications of stem cell–based therapies. This breakout session is designed to review key FDA requirements related to regulatory approval of stem cell-based therapies, including application of human subject protections, investigational new drug and approval requirements, and potential application of new post-market authorities to FDA-approved indications for stem cell-based therapies. Kalah Auchincloss and others will cover ethical and social justice concerns related to clinical use of stem cell-based therapies. Attendees will hear perspectives and advice from FDA, industry, academia and legal counsel.
The 111th Congress: What Happened in the 1st Session and What’s to Come
Wednesday, May 5, 4:00 pm – 5:30 pm
2009 will go down as a legendary year in the battle over health reform. This session will review the just-finished legislative session and accompanying regulatory initiatives and examine what the rest of the president’s term will hold for stakeholders in the biotechnology arena. Listen to the podcast with Barrett Thornhill here: http://biotech-now.org/2010/03/31/podcast-barrett-thornhill-foley-hoag